AU669140B2 - Antiviral activity of extract of cactus - Google Patents

Description

OPI DATE 19/07/93 APPLN. ID 30907/92 II II III 11II 1llUl I 1111 AOJP DATE 16/09/93 PCT NUMBER PCT/GB92/02272 III l II AU9230907

(PCT)

(51) International Patent Classification 5 (11) International Publication Number: WO 93/11779 A61K 35/78 Al (43) International Publication Date: 24 June 1993 (24.06.93) (21) International Application Number: PCT/GB92/02272 (22) International Filing Date: 7 December 1992 (07.12.92) Priority data: 9126393.9 12 December 1991 (12.12.91) GB (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).

Published With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(71X72) Applicants and Inventors: SKINNER, Gordon, Robert, Bruce [GB/GB]; Harborough Bank:, Old Warwick Road, Lapworth, Warwickshire B94 6LD EZRA, Menahem, Israel [GB/GB]; 5 Alba Gardens, London NWII (GB).

(74) Common Representative: SKINNER, Gordon, Robert, Bruce; Harborough Banks, Old Warwick Road, Lapworth, Warwickshire B94 6LD (GB).

669140 (54) Title: ANTIVIRAL ACTIVITY OF EXTRACT OF CACTUS (57) Abstract The object of this invention is to provide a safe medicament from a cactus extract prepared from Opuntia streptacantha which will inhibit intracellular virus replication and inactivate extracellular virus. Intracellular inhibition of virus replication was also noted on pre-incubation of uninfected cells in medium containing cactus extract with removal of the extract prior to virus infection of cells. Inhibition cf virus replication was obtained with both DNA and RNA viruses, for example herpes simplex virus of the herpesvirus group, inf .enza virus of the myxovirus group, respiratory syncytial virus of the paramyxovirus group and human immunodeficiency virus of the lentivirus group. There is evidence that the active inhibitory component(s) of the extract are protein in nature and reside mainly in the wall of the cactus plant rather than in the cuticle or inner sap.

i-t WO 93/11779 PCT/GB92/02272 ANTIVIRAL ACTIVITY OF EXTRACT OF CACTUS TECHNICAL FIELD This invention relates to antimicrobial properties identified in cactus plants in particular Opuntia streptacantha; the antiviral properties comprises inhibition of replication of viruses in cells and secondly inactivation of extracellular infectious virus particles. There is inhibition of intracellular virus replication when the virus-infected cells are incubated with extract of cactus in the incubation medium but also by pre-incubation of the cells in extract-containing medium with removal of this medium prior to virus infection of the cells. The field of this invention extends to both DNA and RNA viruses and is operative in human and non-human cell lines; in addition the field extends to treatment of human and non-human species towards prevention or treatment of virus infections.

BACKGROUND ART A number of plant extracts have been shown to have antiviral effects in terms of inhibiting the replication of viruses in invitro assay systems. As examples, inhibition of replication of herpes simplex virus type 1 by Geranium sanguincum LVIII, influenza, herpes simplex and human immunodeficiency virus by pine cone antitumour substance, murine cytomegalovirus by Chlorella vulgaris and poliovirus by Ulex europaeus have been reported (Zgorniak-Nowosielska et al 1989, Nagata et al 1990, Ibusuki et al 1990, De Rodriguez et al 1990, Sakagami et al 1989). In addition, a number of substances from plants are capable of neutralising the infectivity of viruses invitro; some of these substances are lectins, for example Concanavalin A from Conovalia ensiformis will neutralise infectivity of herpes simplex virus, human cytomegalovirus, Epstein-Barr virus and human immunodeficiency disease virus (Ito and Barron 1974, Ito et al 1978, Khelifa and Meneces 1982, Lifson et al 1986).

Plant extracts have been shown to inhibit replication of other non-viral micro-organisms, namely bacteria and mycobacteria SUBSTITUTE SHEET L l n l

A

WO 93/11779 PCT/GB92/02272 (Macfoy et al 1990, Grange et al 1990) and protozoa for example malaria and trypanosomes (Ghandi et al 1990, Igweh et al 1989).

There is 'urgent need for effective non-toxic and inexpensive products to prevent, control or treat virus infections of vertebrates, non-vertebrates and plant species. In human subjects, available medications for virus infections are extremely limited and present drugs tend to be expensive or toxic; Acyclovir (Zovirax) is a useful parenteral, oral and topical medication for herpes simplex virus and varicella-zoster virus infections but is expensive and many patients are not prescribed this drug by their medical practitioners on account of cost particularly in the United Kingdom where there has been increasing pressure and restriction on family practitioner budgets within recent years.

Gancyclovir for the treatment of cytomegalovirus infections and Zudovadine for human immunodeficiency virus infections (Aids) are both expensive and highly toxic drugs and only offer limited promise in the therapy of these increasingly important infections.

A second problem with certain presently available antiviral drugs is that they tend to operate on only virus-infected cells; this is most notable with Acyclovir where the molecule acycloguanosine is phosphorylated to the monophosphate by the virus-coded enzyme thymidine kinase with only a low level of phosphorylation by uninfected cells and only at high concentrations of the drug. Thus the inhibitory effect of these drugs depends defacto on virus macromolecular events in the cell to initiate its operative mechanism. There is thus less prospect for such drugs in terms of prevention of virus replication at both the cellular level and the therapeutic level in a multicellular host.

Cactus plants and extracts of said plants have been used for decorative, nutritional and medicinal purposes. As an example, extracts of Opuntia Streptacantha have been used for some years as oral hypoglycaemic agents in the control of diabetes and of special interest to the subject matter of this specification a number of plants support virus growth without detriment or even with benefit to the plant; alternatively, virus infection ISUBSTITUTE SHEET SUBSTITUTE SHEET

I

WO 93/11779 PCT/GB92/02272 can result in pathological damage or death to the plant (Delay 1969; Koenig 1972; Boiko et al 1972; Nelson and Tremaine 1975).

It is therefore surprising that cactus extracts will inhibit the intracellular replication of viruses and will inactivate extracellular viruses.

DISCLOSURE OF INVENTION This invention teaches that pre-incubation or incubation of cells with extracts of cactus plants will reduce replication of DNA and RNA viruses and at appropriate concentrations will inhibit synthesis of any new infectious virus particles; the extract will also inactivate extracellular virus.

In the experiments to be described in this disclosure, the dried powder from one capsule was suspended in 5mls of growth medium usually Eagles modified medium containing 10% calf serum and 10% tryptose phosphate broth for 15 minutes at 37°C centrifuged at 800g for 10 minutes, the supernatant recentrifuged under the same conditions and this second supernatant used as stoc. solution; this solution usually contained aproximately 60mgm protein per ml. The extract was routinely filtered through 0.45pm Millipore filters before use.

Stock solutions were normally freshly prepared for experimentations.

The fr. owing experiments are presented to indicate salient feat'- -s of the invention by way of example.

1. Inhibition of replication by incubation of HSV-2 virus-infected cells in medium containing cactus extract Monolayers of baby hamster kidney cells (BHK-21) were infected with 1 plaque forming unit (pfu) per cell of HSV2; following 1 hour absorption at 37 0 C, the monolayers were washed twice with medium and appropriate concentrations in 3mls of medium of a centrifuged filtered preparation of Opuntia streptacantha added to the monolayers. One monolayer was put to -70 0 C to provide estimate of input level of virus, namely the amount of virus SUBSTITUTE SHEET WO 93/11779 4 PCT/GB92/02272 absorbed to the monolayers at time zero prior to incubation and virus replication. Following incubation for 24 hours at 37 0

C

in a gassed (CO 2 incubator, the medium was removed and intracellular virus titrated following disruption of the cells by ultrasonic vibration; virus was titrated by the suspension plaque assay method of (Russel et al (1962)).

;he results indicate that the extract will reduce virus replication over 10 fold at a concentration of 3.5mg/ml and will reduce replication to input levels (where there is no virus replication) at a concentration of 15mg/ml of incubation medium. There is therefore evidence of inhibition of virus replication by addition of this compound to the growth medium.

Data for other viruses is indicated in Table 1; there was significant inhibition of replication of DNA and RNA viruses including the retrovirus human immunodeficiency virus (HIV).

It was also found that replication of HSV2 in organ culture explants of human cervix was inhibited by 3.5 Logo following addition of 15mgm per ml of extract to the incubation medium.

This indicates that the active components of the extract will penetrate and operate in virus-infected contiguous whole tissue which more closely resembles in-vivo conditions than obtain in cell culture.

2. Inhibition of virus replication by pre-incubation of cells in cactus containing medium a. Type 2 herpes simplex virus; 24hr pre-incubation Monolayers of BHK baby hamster kidney cells (cell line BHK21 Mcpherson Stoker 1962) were prepared by additon of 4 X 106 cells to 5cm plastic petri dishes and allowed to incubate i overnight to form a sub-confluent monolayer. The medium was removed and replaced by medium containing the following concentration of Streptacantha opuntia namely 1.8mg per ml of medium to 15mgs per ml in two-fold dilution steps and the cells allowed to incubate in the cactus containing medium for a further 24 hours. The cactus-containing medium and cactus-free medium on control monolayers were removed and the cells washed twice with fresh cactus-free medium followed by addition of 106 plaque forming units of type 2 herpes simplex SUBSTITUTE SHEET WO 93/11779 PCT/GB92/02272 virus strain in 2ml of medium. The virus was allowed to absorb for 1 hour at 37 0 C after which it was removed and 4ml of fresh medium added. The virus was allowed to replicate within the cells for a further 24 hours after which the supernatant medium was harvested and stored separately from the virus infected cells which were removed from the Petri dish by a rubber policeman and then resuspended in lml of water and stored at -700C.

Both the infected cells and the supernatant were thawed, the infected cells disrupted by ultrasonic vibration and the sample titrated by suspension plaque assay by the method of Russell (1962).

The results are indicated in Table 2. There was a significant reduction in replication of intracellular virus which correlated with increased concentrations of extract in the medium. There was also a reduction in the titre of extracellular virus as measured in the supernatant medium (Table 2).

b. Type 2 herpes simplex; influenza A virus. 48hr pre-incubation An identical experiment with 48hr pre-incubation using type 2 herpes simples and influenza virus (influenza A NWS strain) was carried out (Table There was a similar reduction in replication of both viruses with no replication in medium with a. concentration of more than 3.8mgs per ml. Comparison of the reduction in virus titre for type 2 herpes simplex virus in cells with only 24hr pre-incubation with cactus extract indicated little difference a favourable finding suggesting that prolonged pre-incubation of cells in the extract may not be necessary for a significant reduction in virus replication.

Similar results were obtained using a simple water-extraction preparation from a fresh cactus plant; 30g of fresh cactus which had been transported from Mexico to the U.K. were dried in 10ml of sterile water, crushed and incubated at 25 0 C for 3hrs. The liquid portion was withdrawn subjected to ultrasonic vibration of 4 minutes in a Megason water bath sonicator, this constituted the stock solution from which appropriate dilutions SUBSTITUTE SHEET WO 93/11779 6 PCT/GB92/02272 were made in Eagles's medium with 10% calf serum and tryptose phosphate broth.

As it is known that certain constituents of plants for example lectins are capable of virus neutralisation, a series of experiments where BHK21 cells were treated with cactus extract were examined as cell extracts for neutralising activity against type 2 herpes simplex virus. There was no evidence of virus neutralisation by the cell extract which therefore did not contribute to the aforesaid reduction in intracellular virus replication.

3. Specificity of virus inhibition by extract The effect of cactus extract on synthesis of virus (HSV2) polypeptides and uninfected cell polypeptides was investigated by examining the uptake of 3 5 S-methionine into trichloro-acetic acid precipitable polypeptides which were then identified by autoradiography (Table While important virus polypeptides were not evident at 15mg/ml and were reduced in intensity at of extract in medium, there was no loss of uninfected cell polypeptides at 15mg of extract per ml of medium.

4. Evidence that active components of the extract are likely to be protein in nature Prior to addition of extract to medium the extract was pre-treated with pronase under conditions indicated in Table and with trypsin under conditions where the extract was added prior and following virus infection (Tables 6a and 6b respectively). There was a reduction in the virus inhibitory effect of the extract which related (approximately) to increasing concentration of the proteolytic enzyme in the extract. In addition, liquid phase extraction with ether and chloroform did not reduce viral inhibitory activity while precipitation with acetone and reconstitution to the same concentration did not effect the virus inhibitory activity (Table Finally, there was no significant reduction in virus inhibitory activity of the extract following dialysis.

Therefore, it seems likely that the active components were SUBSTITUTE

SHEET

WO 93/11779 7 PCT/GB92/02272 protein in nature and nc; members of the alkaloid, flavanoid or tripterpene groups whl n are found in various types of plants including.cacti and are also known to have antiviral properties.

Location of inhibitory activity to wall of plant The different parts of the cactus plant, namely cuticle wall and inner sap were extracted and tested at the concentrations as given in Table 8; it should be noted that these concentrations do not correspond with other concentrations in this disclcsure as these are obtained from the fresh plant and are not concentrated dried powders. It is clear that the virus inhibitory activity resided in the wall of the plant and not the cuticle or inner sap.

6. Inactivation of extracellular virus (HSV2) by cactus extract Extracellular cell-free HSV2 was incubated at 37 0 C for 1 and 24 hours with varying concentrations of cactus extract in Eagles medium; virus was also incubated with medium alone (cactus free) as a control (Table There was significant reduction in titre of HSV2 at both 1 and 24 hours.

Thus the cactus extract inhibits replication of virus within cells and in addition neutralises or inactivates extracellular virus.

7. Evidence that virus inhibitory levels of active components are nresent in human sera following ingestion of cactus extract A patient ingested eight capsules per day (2.4gms per day) in divided doses of 300mg in each capsule for five days; a blood sample was drawn prior to ingestion of the capsules and four hours following ingestion of the last capsule. The serum was separated off and added to medium in BHK21 cells infected with herpes simplex virus type 2 (HSV2) or equine herpes virus I (EHVl); virus yields from these cells were compared to yields SUBSTITUTE SHEET -i p, WO 93/11779 PC/GB92/O0272 from virus-infected cells incubated in cactus free medium (Table Replication of HSV2 was (as expected) reduced in the presence of both pre-ingestion and post-ingestion serum; this was explicable on account of high HSV2 neutralising antibody levels in this serum operating either by reducing the spread of virus from cell to cell or by inhibition of virus release from virus infected cells. However there was a significantly higher level of inhibitio' -f virus replication with the serum removed following ingestion of the cactus extract indicating an additional inhibitory effect over the pre-ingestion serum.

Towards examining if this effect would be obtained with a herpes virus of animal species namely equine herpes virus I (EHVl) and, perhaps more importantly to use a virus wherein there are no neutralising antibodies in human sera (thus excluding the complication which obtained with HSV2) the test was repeated with this virus in the same experimental system.

There was insignificant reduction in virus replication with the pre-ingestion serum while in the serum removed following ingestion of the extract there was a significant reduction (0.66 Log, 0) indicating that this serum had acquired a level of active components from ingestion of the extracxt that inhibited the replication of EHVl in this laboratory test system.

8. Clinical efficacy of extract The cactus extract prepared from Opuntia streptacantha has been tested in patients with troublesome recurrent herpes genitalis towards modifi-,'ion of tho frequency and severity of recurrences (Table 11 Patients were given four to six capsules per day as indicated in Table 11. The pattern of disease following medication was compared to the pattern prior to medication which was obtained in a prospective fashion in anticipation of instituting treatment with the plant extract in three months time once three months information on the pattern of the disease had been established. Patients were interviewed and given a questionnaire at two months following institution of medication and in addition asked to give an opinion as to whether the treatment had improved the pattern of disease, made SUBSTITUTE SHEET' WO 93/11779 PCT/GB92/02272 9 it worse or had not changed the pattern at all. The results of this preliminary investigation are indicated in Table 11; every patient had evidence of improvement in terms of pattern of disease and 17 of the 20 patients reported improvement.

It is acknowledged that this study was neither placebo-controlled nor double-blinded but serves to indicate an encouraging effect on this clinical assessment of a limited number of patients; in my opinion I have found this extract to be the most encouranging form of treatment during 20 years experience of this condition which has included use of Acylovier, Immunovir and other proprietory preparations designed to modify the pattern of this disease.

The extract has been used at six capsules per day in 4 patients with an acute episode of herpes labialis and in 8 patients during an acute episode of herpes genitalis. There was a decrease in duration of herpetic lesions and extent of vasiculation when the course of the episode was compared to the usual pattern of disease (when extract was not used) although it is acknowledged that the latter information is retrospective.

The extract was used as a local applicant at a concentration of 100mg per ml in sterile saline to five patients with episodes of oral herpes labialis; patients were asked to apply the lotion eight times per day and particularly before retiring to sleep at night. Every patient reported benefit in terms of reduced healing time and less discomfort following rec-ular application of the lotion during the five days of treatment.

The formulation of the lotion for herpes labialis or cther facial herpetic eruptions may be modified in the future as the brown colour and its slightly earthy taste was not particularly pleasing to two of the female patients although this did not result in cessation of treatment.

In summary there is evidence of benefit from the extract in terms of modification of the pattern of recurrent herpes genitalis and treatment of acute episodes either by oral ingestion or as a local medicament in the form of a iction.

There have been no side effects from either oral ingestion of local application of the extract.

SUBSTITUTE SHEET WO 93/11779 PCT/GB92/022721

REFERENCES

Zgorniak-Nowosielska, I. et al. Acta Microbiol. Buig. 1989, 24 3-8.

Nagata, K. et al. Antiviral Res. 1990, 13 11-21.

Ibusuki, E. et al. Nat. Immunol. Cell Growth Regnt. 1990, 9 121-128.

De Rodriguez, et al. Planta Med. 1990, 56 59-62.

Sakagami, H. et al. Anticancer Res. 1989, 9 1593-8.

Ito, M. and Barron, A.L. J. Virol. 1974, 13 1312-1318.

Ito, M. Girin, L. and Barron A.L. Arch. Virol. 1978, 57 97-105.

Rhelifa, R. and Meneces. 3. Virol. 1982, 42 402-410.

Lifson, 3. et al. 3. Exp. Medicine. 1986, 14 2101-2106.

Macfoy, C. et al. 3. Ethnopharmacol. 1990, 28 323-328.

Grange, 3.M. 3. Applied Bacteriol. 1990, 68 587-591.

Ghandi, M. et al. 3. Ethnopharmacol. 1990, 29 51-57.

Igweh, A.C. et al. Anm. Trep. Med. Parasitol. 1989,.83 527-534.

Delay, C. Acad. Sci. (Paris) 1969, 269 (16) 1510-1513.

Koenig, R. virology 1972, 50 263-266.

Boiko, A.L. et al. Mikrobiol. Zh. 1972, 34 523-525.

Nelson, M.R. and Tremaine, J.H. Virology 1975, 65 309-19.

SUBSTITUTE SHEET

I

P

WO 93/11779 PC/GB92/02272 Russel, W.C. Nature. 1962, 195 1028-1029.

MacPherson, 1. and Stoker, M. Virology 1962, 16 147.

I SUBSTITUTE SHEET M 1MM WO 93/11179 WO 9311779PCr/GB92/02272 12 Table 1. Inhibition of replication of DNA and RNA viruses.

Log,,~ reduction Treatment Pre-infection in virus titre of cells Post-infection DNA Viruses Herpesviruses: Herpes simplex type 2 Cytomegalovirus" Pseudorabies rquine herpesvirus I Bovine zmanuilitis 2.6 0.5 0.6 2.3 0.9 RMViruses Influenza A 2.3.

Respiratory syncytial disease virus 0.1 0.9 HIV 2.3 Extract was used at a concentration of 3.5mg/mi. Cytomegalovirusa had higher inhibition of replication on post-infection than pre-infection treatment of cells; this probably relates to the longer incubation times of this virus (3-4 days) and consequently longer exposure to the components of the extract.

SUBSTITUTE SHEET I

A

PCT/GB92/02272 WO 93/11779 1 3 Table 2. Effect of pre-incubation of cells for 24hr by cactus extract .on replication of type 2 herpes simplex virus Concentration of cactus extract (per ml]. medium) Log 10 viras titre per nl Log 10 reduction virus titre Intracellular Extracellular Intracellular Ectracellular Mgms 7. 5 mgms 3. 7 mgms 1. 8 mgms 0 Mgms 3.7 3.6 3.7 3.9 SUBSTITUTE SHEET Ii Table 3. Effect of pretreatment of cell HSV2 and influenza A virus for 48hrs by cactus extract on the replication of 0

'S.

-a a ~0

C

-I

Xc

M

Concentration of cactus extract (per ml medium) 7.5mg 3.7mg 1.8mg 0.9mg 0.45mg 0mg Log 1 0 titre per ml.

(MSV2) 0oj reduction in virus titre

(HMV)

5.1 4.5 5.4 6.4 7.1 7.1 LIAgqL, virus titre per ml (influenza A) 2.5 2.7 3.7 3.3 5.1 5.3 Logl 0 reduction in virus titre (influenza A) 3.3 2.3 2.7 0.9 0.7 Input virus Plant extracts have been shown to inhibit replication of other non-viral micro-organisms, namely bacteria and mycobacteria SUBSTITUTE SHEET 3 WO 93/11779 PCT/GB92/02272 Table 4. Inhibition of HSV2 but not host cell polypeptide synthesis; labelling at lhr 16hr of infection.

Concentration of extract (per ml medium) Virus (HSV2) infected cflls (BHK-21) Uninfected cells (BHK-21) mgm mgm Omgm Reduced intensity and disappearance of several polypeptides Reduced intensity of several polypeptide Every virus polypeptide represented No loss of cell polypeptide No loss of cell polypeptide Every cell polypeptide represented These differences were detected by protein anlaysis and by autoradiographic detection of synthesised 3 5 S-methionine labelled polypeptides (Figure I).

SUBSTITUTE SHEET 1.i j WO 93/11779 PCr/GB92/02272 16 Table 5. Effect of pronase on inhibitory activity of extract Treatment*, concentration of extract (per ml meditum) Log 10 virus titre per ml Lgreduction in virus titre No pronase added; no mock treatment: 6.2 6.7 No pronase added; mock treated with PBS for 2hr at 37"C: 6.3 6.6 6.7 Pronase added at 0.5 mgnmAul for 2hr at 37*C: Pronase added to extract of disrupted hamster kidney cells: 1.2 mgm 0.1 mgm 0.6 mgm 0 mgm Input virus post absorption SUiBSTITUTE SHEET WO 93/11779 WO 9311779PCr/GB92/02272 17 Table 6a. Effect of trypsin on inhibitory activity of extract; pre-infection treatment of cells Treatment; Concentration of extract (per ml mdim) Log, 0 virus titre per ml reduction in virus titre No trypsin added; in m~ock treatment: 1.2 mgm 0.6 mgm 0.3 mgm No trypsin added; with PBS: 1.2 mgm 0.6 mgm 0.3 mgm Typtsin added for at 37" C 1.2 mgm 0.6 mgm 0.3 mgm 0 mgm mock treatment 10 mins Input virus SUBSTITUTE SHEET WO 93/11779 WO 9311779PCI'/GB92/ 02272 18 Table 6b. Effect of trypsin on inhibitory activity of extract post-infection treatment of cells Treatment; concentration of extract (per ml mediumi) Log 10 virus titre per ml Log 10 reduction in virus titre No trypsin added; no mock treatment: 0. 6 mgm 0. 3 mgm No trypsin added; mock treatment with PBS for 10 min at 37'C: Trypsin added for 10 midn at at 120mgm/ml 370 C: 7.77 7.81.

7.9 0 mgm input virus post absorption SUBSTITUTE SHEET -4 WO 93/11779 WO 9311779PCr/GB92/02272 19 Table 7. Effect of lipid solvents on inhibitory activity of extract Treatment; concentration of extract (per ml] medium) Logl 0 virus titre per ml Lo,0reduction.

in virus titre No solvent added: 12 mgm 6 mgm Ether: 12 mgm 6 mgm Chloroform: 12 mgm 6 mgm Acetone precipitation: 12 mgm 6 mgm 0 Mgm Input virus post absorption SUbSTITUTE SHEET 41 WO 93/11779 PCT/GB92/02272 Table 8. Distribution of inhibitory activity in extract from different parts of the plant leaf Preparation Concentration qf extract Log 1 0 virus titre per ml].

(per ml] medium) Log,, reduction in virus titre Whole leaf Outer covering (Cuticle wall) Cuticle Wall Inner Sap Control medium 600mgm 600mg~t- 0.3 0.0 0.6 0.0 22Omgn <400ingm 600mgDm OmgM SUBSTITUTE SHEET i 1 WO 93/11779 21 PCT/GB92/02272 Table 9. Inactivation of extracellular virus (HSV2) Concentrations of extract titre titre virus per ml 24hr <2.0 <1.0 <1.0 Logo, reduction in virus titre Omgm 24hr >2.8 >2.8 >2.8 1.7 Virus and extract were reacted at 37°C in Eagle's medium containing 10% calf serum and 10% tryptose phosphate broth. The reaction was stopped by dilution into cold medium which also reduced the concentration of extract to below <0.07mgm per ml at which there would not be inhibition of virus replication by the extract.

SUBSTITUTE SHEET I i WO 93/111779 PCT/GB92/02272 22 Table 10. Inhibition of replication of type 2 herpes simplex (HSV2) and equine herpes virus I (EHV1) by serum from a patient ingesting the extract.

Log 0 o reduction in virus titre HSV2 Prior to ingestion of extract Following ingestion of extract Differences in inhibitory activity between pre and post ingestion EH1 0.16 0.66 0.50 Serum was at 25% concentration in medium for HSV2-infected cells and at 40% concentration for EHV-1 infected cells.

SUBSTITUTE SHEET r

-L

Table 11. outcome of Initials Sex of patient treatment in patients with recurrent herpes genitalis Dose (no. capsules) No. recurrence during x duration (days) 3/12 prior to 2/12 following to medication medication 4 x15d 16 2 very smal 6 x14d 1 0 Patients opinion of treatment

I.B.

M.E. 3 C. F.

S.F.

1 S.F. 2

A-G-

.1 6 x 14d 4 x 20d 6 x 28d 6 x 60d 4 x 56d 4 x 7d 3 x 12d 2 x 14d a x 70d 6 x 28d 6 x 28d 1 reduced symptoms 1 less tingling 0 0 3 reduced duration 3/4 2 1 began after tablet stopped

M.R.

J.s.

C.T.

P.W.

M.A.

C.M.

M.E.Z.

G.W.

I .H.

L.M.

S.K.

6 x 28 6 x 28 6 x 7d 3 x 21d 6 x 28d 6 x 28d o no further recurrence for 9 months 1 3 0 0 C02

C

CO

C

-4 mO 0)

M

M

Mean

S.E.

Proportion "impovd 20/20 (100%) 17/20 FVUTTOES Improved very much improved Unchanged Worse 0 7

F

Claims (16)

1. A method of inhibiting replication of DNA and RNA viruses using an extract prepared from a cactus plant.

2. A method of inhibiting replication of DNA and RNA viruses using an extract prepared from a cactus plant where the cells are pre-incubated in the cactus extract-containing medium.

3. A method of inhibiting replication of DNA and RNA viruses using a cactus extract which is protein in nature.

4. A method of inhibiting replication of DNA and RNA viruses using an extract which is protein in nature prepared from a cactus plant where the cells are pre-incubated in cactus extract-containing medium. A method of inhibiting replication of DNA and RNA viruses using a cactus extract prepared from the plant Opuntia streptacantha.

6. A method of inhibiting replication of DNA and RNA viruses using a cactus extract prepared from the plant Opuntia streptacantha where the cells are pre-incubated in medium-containing extract of Opuntia streptacantha.

7. A method of inhibiting replication of DNA and RNA viruses using a cactus extract which is protein in nature and prepared from the plant Opuntia streptacantha.

8. A method of inhibiting replication of DNA and RNA viruses using an extract which is protein in nature prepared from the plant Opuntia streptacantha where the cells are pre-incubated in medium-containing extract of Opuntia streptacantha.

9. Use of wall (excluding inner sap and outer cuticle) of cactus plant according to claims 1, 2, 3 or 4. t SUBSTITUTE SHEET WO 93/11779 26 PCT/GB92/02272 Use of wall (excluding inner sap and outer cuticle) of cactus plant prepared from Opuntia streptacantha according to claims 5, 6, 7 or 8.

11. A method of inactivating DNA and RNA extracellular virus by cactus extract.

12. A method of inactivating DNA and RNA extrcellular virus by cactus extract prepared from Opuntia streptacantha.

13. A method of preventing virus disease in human and non-human species using cactus extract.

14. A method of modulating the course of virus disease in human and non-human species using cactus extract. A method of preventing virus disease in human and non-human species using cactus extract prepared from Opuntia streptacantha.

16. A method of modulating the course of virus disease in human and non-human species using castus extract prepared from Opuntia streptacantha.

17. A method of preventing or modulating virus disease using cactus extract which depends on both inhibition of virus replication and inactivation of extracellular virus.

18. A method of preventing or modulating virus disease using cactus extract prepared from Opuntia streptacantha which depends on both inhibition of virus replication and inactivation of extracellular virus. t SUBSTITUTE SHEET h SUBSTITUTE SHEET L INTERNATIONAL SEARCH REPORT Intetional application No. Pr.T/GB 92/02272 A. CLASSIFICATION OF SUBJECT MATTER IPCS: A61K 35/78 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentattion searched (cLasmficiauon system followed by claissification symnbols) A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, wit indication, where appropriate, of the relevant. Passages Relevant to claim Nc X US, A, 3860710 (SERMANNI-GIOVANNOZZI ET AL), 1-12 14 January 1975 (14.01.75) A Dialog Information Services, file 5, BIOSIS, 1-12

68-90/Nay, Dialog Acc.No.7405468, Biosis Acc.No. 89056487, Zgorniak-Nowosielska I. et al: "A study on the antiviral action of a polyphenolic complex isolated from the medicinal plant geranium- -sanguineum L. VIII. Inhibitory effect on the reprod~ction of herpes simplex virus type 1", Acia- icrobiol Bulg. 24 1989, 3-8 Further documents are listed in the continuation or Box C. ElSee patent family annex. Special categories of cied docuament IT, ta dn published after the ineratiuonal filing daeorp W documenot defining tile general state of the ant which is amt considered dae and cot in or ither unddy the uivccanon twd1 to be of partoslar relevance teptcpso hoyudryn h n~o 'E ciier docuament but published an or after the international Miing date IX, doosmuat of ogirsicsa nievanoc the claimed inventon cannotb d~~~~cinnit cnsdee Wbt a hrwdui n nftlctii)O hihi vet or cannot be considered to involve an inventive cited in eablish the publication date of another musanon or otherwhstedcmiataeaon special meaom (as specified) doosmeat of pamticular Weevance: the clamed inventon cannotb document refenag to an oral, dislosure, use, exhibition or other cosdrdto involve an invetive step when the documient is document cuomiined wirt h naaalfligdt u aeta th one or more other such domsments, sacn corna 'PI ocuentpublshe pror o te iterntioal ilig dae bst aw han being obvious to a person sicilled in the art the priority date claimed document member of the same paum family Date of the acual completion of the international search Date of mailing of the international search report 29 March 1993 P.7 APR 1993 Nana and enniline aarcsi of [fie ISA/ Authorized officer 9Euroocan Patent ornon, P.B. Sits Patentizan 2 NL-2280 KY Rijswijk Tel. 3 340.2040. Tx. 31 651 coo nW. CAROLINA PALMCRANTZ L7 0)Fa: (+31.70) 340.3016 Form PCr/ISA/210 (second sheet) (July 1992) Th INTERNATIONAL SEARCH REPORT lfrnational application No. PCT/GB 92/02272 C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages fRelevant to claim No. A Dialog Information Services, file 5, BIOSIS, 68-90/May, Dialog Acc. No. 7411409, Biosis Acc. No. 89062428, Meckes-Lozoya A M et al: "Hypoglycemic activity of opuntia streptacantha throughout its annual cycle", Am J Chin Med 17 1989, 221-224 1-12 Form PCT/ISA/210 (conunuatlon of second sheet) (July 1992) SUBSTiTUTE SHEET I SA -9273 ITRNATIONAL SEARCH REPORT Information on patent family members nte-rnational application No. 26/02/93 IPCT/GB 92/02272 Patent document Publication Patent family duliatio cited in search report date member(s) dt US-A- 3860710 14/01/75 NONE F~orm PCT/ISA/210 (patent family annex) (July 1992)